Références
1. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation
in patients with low-risk thyroid cancer. N. Engl. J. Med. 2012 mai 3;366(18):1663-73.
2. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and
thyrotropin alfa in thyroid cancer. N. Engl. J. Med. 2012 mai 3;366(18):1674-85.
3. Clerc J, Bienvenu-Perrard M, de Malleray CP, Dagousset F, Delbot T, Dreyfuss M, et al. Outpatient thyroid
remnant ablation using repeated low 131-iodine activities (740 MBq/20 mCix2) in patients with low-risk
differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 2012 mars;97(3):871-80.
4. Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, Fieffé S, et al. Impact on overall survival of
radioactive iodine in low-risk differentiated thyroid cancer patients. J. Clin. Endocrinol. Metab. 2012
mai;97(5):1526-35.
5. Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, et al. Delayed risk stratification,
to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity
in differentiated thyroid cancer patients. Eur. J. Endocrinol. 2011 sept;165(3):441-6.
6. Brassard M, Borget I, Edet-Sanson A, Giraudet A-L, Mundler O, Toubeau M, et al. Long-Term Follow-Up of
Patients with Papillary and Follicular Thyroid Cancer: A Prospective Study on 715 Patients. Journal of Clinical
Endocrinology & Metabolism. 2011 mars 9;96(5):1352-9.
7. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, et al. Second primary malignancy
risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009
mai;19(5):451-7.
8. Iyer NG, Morris LGT, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-
risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011 oct 1;117(19):4439-46.
9. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on
the uptake of ablative dose of iodine-131. Thyroid. 1994;4(1):49-54.
10. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, et al. Iodine biokinetics and
dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international
controlled study of ablation after rhTSH or hormone withdrawal. Journal of Nuclear Medicine. 2006;47(4):648-
54.
11. Pacini F. Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in
Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study. Journal of
Clinical Endocrinology & Metabolism. 2005 déc 29;91(3):926-32.
12. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poggiu A, et al. A Comparison of 1850 (50 mCi)
and 3700 MBq (100 mCi) 131-Iodine Administered Doses for Recombinant Thyrotropin-Stimulated
Postoperative Thyroid Remnant Ablation in Differentiated Thyroid Cancer. Journal of Clinical Endocrinology
& Metabolism. 2007 sept 1;92(9):3542-6.
13. Muratet JP, Giraud P, Daver A, Minier JF, Gamelin E, Larra F. Predicting the efficacy of first iodine-131
treatment in differentiated thyroid carcinoma. J. Nucl. Med. 1997 sept;38(9):1362-8.
14. Taïeb D, Jacob T, Zotian E, Mundler O. Lack of efficacy of recombinant human thyrotropin versus thyroid
hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung
metastases. Thyroid. 2004 juin;14(6):465-7.